43.30

0.23% +0.10

After Hours: 43.30

Belite Bio Inc ADR (BLTE)

Overview News Price History Discussions Forecast

Belite Bio Inc ADR stock is currently priced at $43.30, with a 24-hour trading volume of 35,629. It has seen a +0.23% increased in the last 24 hours and a +9.29% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $42.51 pivot point. If it approaches the $44.14 resistance level, significant changes may occur.

Previous Close:

$43.20

Open:

$41.7051

24h Volume:

35,629

Market Cap:

$1.29B

Revenue:

Net Income/Loss:

$-31.63M

P/E Ratio:

-56.96

EPS:

-0.7602

Net Cash Flow:

1W Performance:

+5.79%

1M Performance:

+9.29%

6M Performance:

+10.37%

1Y Performance:

+53.55%

1D Range:

$41.71

$43.35

52W Range:

$11.00

$48.60

Belite Bio Inc ADR Stock (BLTE) Company Profile

Name

Belite Bio Inc ADR

Sector

Healthcare (1215)

Industry

Biotechnology (700)

Phone

858-246-6240

Address

5820 Oberlin Drive, Suite 101, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BLTE's Discussions on Twitter

Belite Bio Inc ADR Stock (BLTE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Maxim Group	Buy
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight
Jul-26-23	Initiated	SVB Securities	Outperform
Aug-01-22	Initiated	H.C. Wainwright	Buy
Jul-01-22	Initiated	The Benchmark Company	Buy

Belite Bio Inc ADR Stock (BLTE) Latest News

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

GlobeNewswire Inc.

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire Inc.

Belite Bio Announces $25 Million Registered Direct Offering

GlobeNewswire Inc.

Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?

Zacks Investment Research

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

GlobeNewswire Inc.

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

GlobeNewswire Inc.

Belite Bio Inc ADR Stock (BLTE) Financials Data

Belite Bio Inc ADR (BLTE) Net Income 2024

BLTE net income (TTM) was -$31.63 million for the quarter ending December 31, 2023, a -150.09% decrease year-over-year.

Belite Bio Inc ADR (BLTE) Earnings per Share 2024

BLTE earnings per share (TTM) was -$1.2342 for the quarter ending December 31, 2023, a -114.27% decline year-over-year.

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.